ACOG: A Toll Road Into Alzheimer’s Long-Term Care

Modest Yet Durable

This will be a “best ideas only” bio substack providing actionable, highly digestible and high conviction value to investors focused on quality not quantity. Disclaimer: Nothing in this article (or substack) is considered investment advice and is solely the opinion of the author.

There is a tendency in biotechnology investing to equate scientific novelty with investment attractiveness. The more exotic the modality, the more novel the target, and the more ambitious the biological objective, the more attention a company tends to receive. This is particularly true in Alzheimer’s disease, where enormous amounts of capital and scientific effort have been directed toward the ultimate prize: changing the underlying course of the disease. Amyloid antibodies have now established that disease modification is possible, while the industry continues to pursue tau, neuroinflammation, synaptic biology and a growing number of other approaches that could theoretically slow, prevent or one day meaningfully alter Alzheimer’s disease.